These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33527451)

  • 1. Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.
    Begna KH; Gangat N; Al-Kali A; Litzow MR; Hogan WJ; Patnaik MM; Pardanani A; Hook CC; Wolanskyj AP; Elliott MA; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2021 Apr; 96(4):E108-E111. PubMed ID: 33527451
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Othman TA; Mei M; Zhang J; Aldoss I; Stein A; Forman SJ; Marcucci G; Pullarkat V
    Am J Hematol; 2021 May; 96(5):E140-E143. PubMed ID: 33524204
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
    Salhotra A; Aribi A; Ngo D; Zhang J; Sandhu K; Al-Malki M; Ali H; Koller P; Arslan S; Budde E; Khaled S; Dadwal S; Snyder DS; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
    Am J Hematol; 2021 Jun; 96(6):E196-E200. PubMed ID: 33719090
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Pillai R; Sanchez JF; Mei M; Aribi A; Ali H; Sandhu K; Al Malki MM; Salhotra A; Khaled S; Sun W; O'Donnell M; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Oct; 94(10):E253-E255. PubMed ID: 31259427
    [No Abstract]   [Full Text] [Related]  

  • 5. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
    Venugopal S; Maiti A; DiNardo CD; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
    Am J Hematol; 2021 May; 96(5):E154-E157. PubMed ID: 33580980
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
    DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
    Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
    Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
    Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
    Arslan S; Zhang J; Dhakal P; Moran J; Naidoo N; Lombardi J; Pullarkat V; Stein AS; Marcucci G; Yaghmour G; Bhatt VR; Fathi AT; Aldoss I
    Am J Hematol; 2021 Mar; 96(3):E59-E63. PubMed ID: 33227142
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypomethylating agents and venetoclax in acute myeloid leukemia.
    DiNardo CD
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
    [No Abstract]   [Full Text] [Related]  

  • 12. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.
    Wan CL; Liu YQ; Liu FT; Huang YH; Cao HY; Huang SM; Tan KW; Ge SS; Wang M; Liu MJ; Wang ZH; Li Z; Xue SL; Dai HP
    Blood Cancer J; 2024 Aug; 14(1):144. PubMed ID: 39179571
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
    Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
    Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
    Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
    Raedler J; Heyde S; Kolokythas M; Eichinger A; Binder V; Schmid I; Klein C; Feuchtinger T; Albert MH
    Br J Haematol; 2020 Jun; 189(6):e251-e254. PubMed ID: 32342493
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
    Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax with decitabine or azacitidine for AML.
    Das M
    Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.